NCT04385290 2025-09-08
MOSAIC
Technische Universität Dresden
Phase 1/2 Recruiting
Clinical Trials
7 trialsNCT03390296 2023-09-05
OX40, Venetoclax, Avelumab, Glasdegib, Gemtuzumab Ozogamicin, and Azacitidine in Relapsed or Refractory Acute Myeloid Leukemia
M.D. Anderson Cancer Center
Phase 1/2 Completed
NCT03531918 2023-08-30
Gemtuzumab Ozogamicin With G-CSF, Cladribine, Cytarabine & Mitoxantrone for Untreated AML & High-Grade Myeloid Neoplasm
Fred Hutchinson Cancer Center
Phase 1/2 Completed
NCT00766116 2019-02-18
Combination 5-azacitidine and Gemtuzumab Ozogamicin Therapy for Treatment of Relapsed Acute Myeloid Leukemia (AML)
University of California, San Diego
Phase 1/2 Completed
NCT02182596 2014-07-08
MYLOFRANCE2
Acute Leukemia French Association
Phase 1/2 Completed
NCT00038831 2012-08-01
Allo Transplantation With Mylotarg, Fludarabine and Melphalan for AML, CML and MDS
M.D. Anderson Cancer Center
Phase 1/2 Completed
NCT00460447 2007-04-16
Gemtuzumab Ozogamicin Before Allogeneic Stem Cell Transplantation
University Hospital Carl Gustav Carus
Phase 1/2 Unknown